CLINICAL TRIALS

Based on research conducted in our laboratory, we have launched or contributed to several immunotherapy clinical trials. For more information about these active trials, click the links below:

Phase I Trial in Ovarian Cancer

This is an investigator-initiated Phase 1 clinical trial that is led by our collaborator Dr. Anna Tinker.  This study will investigate the safety of combining external beam radiation plus durvalumab, an immune checkpoint inhibitor, in ovarian cancer. The two sites that are participating include BC Cancer Vancouver and Princess Margaret Hospital. AstraZeneca has funded the study and it is currently ongoing and recruiting.  Our laboratory will be conducting research on samples collected from patients on this study to help us identify biomarkers that will help us understand treatment response. 

 

For more information, please click here.

Phase II Trial in Hepatocellular Carcinoma

This is a phase II study to examine the develop, validate and quality test high-dose rate stereotactic body radiation (SBRT) in certain types of hepatocellular carcinoma (liver cancer).  The study is active but no longer recruiting patients as it has met their targets. Our lab is working with the PI, Dr. Roy Ma, to examine how immune responses change during the course of treatment. 

 

For more information, please click here.

Phase III Trial in Prostate Cancer

This is a phase III clinical trial comparing high-dose rate versus low-dose rate brachytherapy (radioactive seeds) as a single treatment for intermediate risk prostate cancer.  This study is currently active and recruiting patients. We are collaborating with the study investigator Dr. Juanita Crook to understand, a) whether we can predict which patients will respond to brachytherapy, and b) whether the immune system plays a role in patient responses. 

 

For more information, click here.

CLINICAL STUDIES

Metabolism and autophagy in memory T cell development

Based on our published studies, we are investigating whether autophagy plays a role in development of memory after vaccination.  There are two study groups, one in which we study patient immune responses after seasonal influenza vaccination, and a second in which we study patient immune responses after yellow fever vaccination. This study will examine the body's natural immune response to vaccination in order to help researchers design more effective vaccines for diseases such as cancer. Specifically, this study aims to uncover genetic differences between healthy individuals that may impact the immune response to vaccination. This is a collaboration with several research groups from British Columbia (Dr. Laura Sly) and our local travel clinics.

 

For more information about participating in the study please contact the Study Coordinator.

 

 

Immune Response to Ovarian Cancer (IROC)

We are actively studying how the immune systems responds to ovarian cancer.  Through our human biospecimen repository, our team is investigating the metabolic interactions between tumors and T cells using mass-spectometry and high-dimensional analysis. This work involves the collection of biospecimens from ovarian cancer patients treated at our cancer centre.  The studies will also include the discovery of novel neoantigens that could be targets for CAR-T cell or adoptive T cell immunotherapy strategies.  The goal is to generate important knowledge about the behavior of ovarian cancers and how best to harness the immune system to attack the cancer cells.  The study is a large team effort by multiple laboratories across multiple disciplines.

 

For more information about the study, please contact a member of the Study team.

 

 

Immune Response to Prostate Cancer (IRPC)

As a sister project, our team has collected over samples from over 160 prostate cancer patients treated at our center.  The goal is to investigate how the immune system changes over time and whether radiation or hormone therapy impacts overall immune responses.

 

For more information about possible studies, please contact the Study Coordinator.